Knight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia Buys 20,000 Shares

Knight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia acquired 20,000 shares of Knight Therapeutics stock in a transaction on Monday, November 11th. The shares were bought at an average price of C$5.15 per share, for a total transaction of C$103,000.00.

Knight Therapeutics Trading Down 1.7 %

TSE:GUD opened at C$5.17 on Tuesday. The stock has a market cap of C$523.26 million, a price-to-earnings ratio of -25.85, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics Inc. has a one year low of C$4.98 and a one year high of C$6.23. The company has a debt-to-equity ratio of 7.62, a quick ratio of 1.79 and a current ratio of 3.41. The business’s 50-day simple moving average is C$5.74 and its 200 day simple moving average is C$5.75.

Wall Street Analysts Forecast Growth

GUD has been the topic of several recent research reports. Stifel Nicolaus raised Knight Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the stock from C$5.75 to C$6.75 in a research report on Tuesday, August 13th. Stifel Canada upgraded shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 12th.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.